CL2019002953A1 - Anticuerpo anti-pd-l1 y uso del mismo. - Google Patents
Anticuerpo anti-pd-l1 y uso del mismo.Info
- Publication number
- CL2019002953A1 CL2019002953A1 CL2019002953A CL2019002953A CL2019002953A1 CL 2019002953 A1 CL2019002953 A1 CL 2019002953A1 CL 2019002953 A CL2019002953 A CL 2019002953A CL 2019002953 A CL2019002953 A CL 2019002953A CL 2019002953 A1 CL2019002953 A1 CL 2019002953A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- fully human
- affinity
- human anti
- ability
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2017028206 | 2017-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019002953A1 true CL2019002953A1 (es) | 2020-01-10 |
Family
ID=63856823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019002953A CL2019002953A1 (es) | 2017-04-18 | 2019-10-16 | Anticuerpo anti-pd-l1 y uso del mismo. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210115143A1 (https=) |
| EP (1) | EP3612565A4 (https=) |
| JP (2) | JP2020517239A (https=) |
| KR (1) | KR102323960B1 (https=) |
| CN (1) | CN110856446A (https=) |
| AU (1) | AU2018256392B2 (https=) |
| BR (1) | BR112019021828B1 (https=) |
| CA (1) | CA3059447A1 (https=) |
| CL (1) | CL2019002953A1 (https=) |
| CO (1) | CO2019012118A2 (https=) |
| EA (1) | EA201900443A1 (https=) |
| MA (1) | MA50038A (https=) |
| MX (1) | MX2019012461A (https=) |
| MY (1) | MY199319A (https=) |
| PH (1) | PH12019502302A1 (https=) |
| SG (1) | SG11201909041SA (https=) |
| WO (1) | WO2018195226A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| US11046769B2 (en) * | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| EP3880227A4 (en) | 2018-11-14 | 2022-11-09 | RubrYc Therapeutics, Inc. | ANTI-CD25 ANTIBODIES |
| EP3880698A4 (en) | 2018-11-14 | 2022-11-30 | RubrYc Therapeutics, Inc. | MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF |
| CN109929037B (zh) | 2019-04-01 | 2023-03-17 | 华博生物医药技术（上海）有限公司 | 针对程序性死亡配体的结合物及其应用 |
| WO2020209645A1 (ko) * | 2019-04-11 | 2020-10-15 | (재) 스크립스코리아항체연구원 | 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도 |
| WO2020216379A1 (en) * | 2019-04-26 | 2020-10-29 | I-Mab | Human pd-l1 antibodies |
| WO2022006091A1 (en) * | 2020-06-29 | 2022-01-06 | Anovent Pharmaceutical (U.S.), Llc | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
| US20230303699A1 (en) * | 2020-08-04 | 2023-09-28 | Exelixis, Inc. | Pd-l1 binding agents and uses thereof |
| WO2023046113A1 (zh) * | 2021-09-24 | 2023-03-30 | 广东菲鹏制药股份有限公司 | 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用 |
| CN120813375A (zh) | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04000747A (es) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| EP3255060A1 (en) * | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP3060581A4 (en) * | 2013-10-25 | 2017-06-07 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| US10835595B2 (en) * | 2014-01-06 | 2020-11-17 | The Trustees Of The University Of Pennsylvania | PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy |
| EP3107569A4 (en) * | 2014-02-20 | 2018-02-21 | Alder Biopharmaceuticals, Inc. | Anti-acth antibodies and use thereof |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| CN108112254B (zh) * | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| WO2018080812A1 (en) * | 2016-10-30 | 2018-05-03 | Henlix, Inc. | Anti-pd-l1 antibodies and variants |
-
2018
- 2018-04-18 EP EP18788069.5A patent/EP3612565A4/en not_active Withdrawn
- 2018-04-18 WO PCT/US2018/028206 patent/WO2018195226A1/en not_active Ceased
- 2018-04-18 MA MA050038A patent/MA50038A/fr unknown
- 2018-04-18 US US16/606,647 patent/US20210115143A1/en not_active Abandoned
- 2018-04-18 AU AU2018256392A patent/AU2018256392B2/en not_active Ceased
- 2018-04-18 SG SG11201909041S patent/SG11201909041SA/en unknown
- 2018-04-18 KR KR1020197032419A patent/KR102323960B1/ko active Active
- 2018-04-18 MX MX2019012461A patent/MX2019012461A/es unknown
- 2018-04-18 EA EA201900443A patent/EA201900443A1/ru unknown
- 2018-04-18 MY MYPI2019006142A patent/MY199319A/en unknown
- 2018-04-18 BR BR112019021828-9A patent/BR112019021828B1/pt not_active IP Right Cessation
- 2018-04-18 CA CA3059447A patent/CA3059447A1/en active Pending
- 2018-04-18 JP JP2019556600A patent/JP2020517239A/ja active Pending
- 2018-04-18 CN CN201880025898.4A patent/CN110856446A/zh active Pending
-
2019
- 2019-10-07 PH PH12019502302A patent/PH12019502302A1/en unknown
- 2019-10-16 CL CL2019002953A patent/CL2019002953A1/es unknown
- 2019-10-29 CO CONC2019/0012118A patent/CO2019012118A2/es unknown
-
2022
- 2022-11-07 JP JP2022178282A patent/JP2023025003A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2019012118A2 (es) | 2020-04-01 |
| AU2018256392B2 (en) | 2024-05-16 |
| MX2019012461A (es) | 2019-12-11 |
| BR112019021828A2 (pt) | 2020-03-24 |
| JP2020517239A (ja) | 2020-06-18 |
| MA50038A (fr) | 2020-07-08 |
| CN110856446A (zh) | 2020-02-28 |
| SG11201909041SA (en) | 2019-11-28 |
| AU2018256392A1 (en) | 2019-10-17 |
| EP3612565A1 (en) | 2020-02-26 |
| CA3059447A1 (en) | 2018-10-25 |
| KR20190141169A (ko) | 2019-12-23 |
| MY199319A (en) | 2023-10-24 |
| JP2023025003A (ja) | 2023-02-21 |
| KR102323960B1 (ko) | 2021-11-10 |
| PH12019502302A1 (en) | 2020-09-21 |
| EP3612565A4 (en) | 2021-06-16 |
| BR112019021828B1 (pt) | 2022-09-20 |
| EA201900443A1 (ru) | 2020-03-06 |
| WO2018195226A1 (en) | 2018-10-25 |
| US20210115143A1 (en) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019002953A1 (es) | Anticuerpo anti-pd-l1 y uso del mismo. | |
| CL2023000895A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| CY1124384T1 (el) | Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3 | |
| CO2020000438A2 (es) | Anticuerpos anti-ctla-4 y sus usos | |
| ZA202201874B (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
| CO2020010277A2 (es) | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl | |
| PH12020500667A1 (en) | Multispecific antibodies and use thereof | |
| MX2016012094A (es) | Composiciones de anticuerpos para tratamiento tumoral. | |
| CL2018003520A1 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. | |
| CL2018003758A1 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458) | |
| BR112019000970A2 (pt) | proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas | |
| CY1124456T1 (el) | Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων | |
| MX2016009444A (es) | Anticuerpos humanos a ligando de muerte programada 1 (pd-l1). | |
| MX2019007554A (es) | Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso. | |
| MX2018000621A (es) | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos. | |
| EA202090204A1 (ru) | Анти-cd137 антитела | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| BR112017001579A2 (pt) | anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos | |
| CO2017005650A2 (es) | Anticuerpos anti-interleucina-33 | |
| MX2017014955A (es) | Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. | |
| CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
| PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
| MX2018013072A (es) | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. | |
| BR112014012590A8 (pt) | Anticorpos anti-cd98 e métodos de uso dos mesmos | |
| PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof |